Hikal Ltd

- For the current year, Hikal plans to complete ongoing capex with INR 200 crores, of which INR 100 crores is already completed. - Some additional funding will be needed from the next quarter (H2 FY '24) to complete unfinished projects. - There will be some debt funding in H2 FY '24, but this will be balanced by incoming equity. - The company expects good profits in H2 FY '24, helping maintain debt-equity ratios around the current level (approximately 0.61). - For the next year, capex will be slightly lower as efforts focus on utilizing existing assets, with no explicit mention of large new fundraising. - Overall, internal cash flows are expected to cover most expansion capex, but some measured debt and equity raising is anticipated to complete existing projects.

- Current year capex planned is around INR 200 crores, with approximately INR 100 crores already completed. - Next year's capex expected to be slightly lower, focusing on filling up existing assets rather than new expansions. - Completion and commissioning of new facilities like the multipurpose Animal Health facility at Panoli are underway; full production ramp-up expected by March-April FY '25. - Continuing investments in new plants, including Crop Protection assets, with commissioning starting soon. - Asset capitalization occurs upon project completion, not at first commercial batch. - Large ongoing capex of approximately INR 500-550 crores over past years, with around INR 480-490 crores expected to be capitalized this year. - Additional funding may be required in H2 for incomplete projects, but internal cash flows and equity infusion will keep debt-equity ratio stable (~0.61). - Focus remains on technology, operational efficiency, and capacity ramp-up for medium to long-term growth.

- Volume growth for H1 FY24: Pharma volumes grew by 4%, Crop Protection volumes degrew by 26%, leading to overall 16% volume decline (Page 16). - Crop Protection volume expected to improve starting Q4 FY24 with channel inventory normalization (Page 16). - Sales growth targets: Management expects top line to grow substantially over the next 3-4 years with a target of INR 3,500-4,000 crores by FY26/FY27 (Page 10). - New product launches and increased CDMO proportion in Pharma to support revenue growth (Pages 4, 11, 15). - Capex completion and ramp-up expected by FY25 to drive incremental sales, with some ramp-up over 1-2 years post-commissioning (Pages 9-10). - Ongoing customer interest and inquiries from new geographies in both Pharma and Crop Protection segments underpin growth optimism (Pages 7, 11, 15).

- Pharma volumes grew 4% in H1 FY24; Crop Protection volumes degrew 26%, causing overall 16% decline. - Signs of improvement in Crop Protection expected from Q4 FY24 as channel inventory normalizes. - New product mix and CDMO business expected to improve margins significantly going forward. - Capex commissioning for new plants anticipated by Q1/Q2 FY25, with ramp-up over 18-24 months. - Revenue growth target of INR 3,500 to 4,000 crores by FY26-FY27 affirmed. - Profitability and margins expected to improve sequentially in H2 FY24 due to cost optimization and better product mix. - EBITDA margin expected to increase 2-3% with CDMO ramp-up in H2 FY24. - Debt levels stable; future expansion capex may require moderate funding but equity infusion and profits expected to maintain debt-equity ratio. - ROE below cost of capital in Q2 FY24 seen as one-off; expected to recover with improved margins and volume growth.

- The earnings call transcript does not specify exact current orderbook or pending order values. - Manoj Mehrotra highlighted increased customer inquiries and audits in the CDMO business, indicating a growing funnel of potential projects. - Several new projects are under development due to increased new customer audits and exploration of new geographical markets. - The Crop Protection business is at advanced stages of discussions with customers for new projects expected to yield positive medium- to long-term results. - Validation batches for Animal Health products are planned over the next 4 to 6 quarters, marking progress towards commercialization. - The company expects CDMO demand to revive and normalization towards Q4 FY '24, implying an increase in orderbook going forward. - Overall, the company is witnessing increased traction and new business inquiries across Pharma and Crop Protection segments, but no specific orderbacklog numbers were disclosed.